Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan - MSN
2 days ago • Google News
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating di.
2 days ago • Google News
2 days ago • Google News